A Phase 1, Open Label, Non-Randomized Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Oral Seladelpar in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects With Normal Hepatic Function
Phase of Trial: Phase I
Latest Information Update: 25 May 2018
At a glance
- Drugs Seladelpar (Primary)
- Indications Liver failure
- Focus Pharmacokinetics
- Sponsors CymaBay Therapeutics
- 17 May 2018 Status changed from recruiting to completed.
- 02 Apr 2018 Planned End Date changed from 1 Mar 2018 to 1 Apr 2018.
- 02 Apr 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Apr 2018.